NCT05518903phase 2recruiting

Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma

Mayo Clinic · with National Cancer Institute (NCI)

ClinicalTrials.gov

130

Enrollment · estimated

Countries · 1 sites

2027-06

Primary completion

1 mo ago

Record updated

Commercial relevance

Trial record references ctDNA / liquid biopsy referenced.

ctDNA / liquid biopsy

Change timeline

No changes detected yet. The first refresh records a baseline snapshot; subsequent refreshes generate field-level changes.

Signals from this trial

New trial
53/100
Opportunity
New phase 2 trial NCT05518903 posted by Mayo Clinic: "Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma".
ClinicalTrials.gov record updated 29 days ago.

Eligibility — raw, for validation

Inclusion Criteria:

* Adults \> 18 years (yrs.) with treatment-naive biopsy-proven PDA or with findings diagnostic for PDA on baseline imaging (CT, MRI, or PET)
* Localized disease expected to undergo surgical resection following neoadjuvant therapy (NAT)
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
* Ability to provide informed consent

Exclusion Criteria:

* Hypersensitivity to any excipients in 68Ga-FAPI-46
* Require emergency surgery
* Non-PDA histology on biopsy
* Histopathologically proven metastatic PDA
* Pregnant or lactating women